Q3 Earnings Forecast for VolitionRX Issued By Zacks Research

VolitionRX Limited (NYSEAMERICAN:VNRX – Free Report) – Equities research analysts at Zacks Research increased their Q3 2026 EPS estimates for VolitionRX in a report released on Wednesday, September 16th. Zacks Research analyst S. Ralston now expects that the medical research company will post earnings of ($0.35) per share for the quarter, up from their prior forecast of ($0.42). The consensus estimate for VolitionRX’s current full-year earnings is ($1.88) per share. Zacks Research also issued estimates for VolitionRX’s Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($1.55) EPS.

Get VolitionRX alerts:

VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.41 million.

Other equities research analysts have also issued reports about the company. Maxim Group reissued a “buy” rating and set a $4.00 price target on shares of VolitionRX in a research note on Thursday, June 18th. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, VolitionRX currently has an average rating of “Hold” and an average price target of $28.00.

Check Out Our Latest Stock Analysis on VolitionRX

VolitionRX Price Performance

Shares of NYSEAMERICAN:VNRX opened at $0.26 on Monday. VolitionRX has a 1 year low of $0.24 and a 1 year high of $14.80. The business has a 50 day simple moving average of $0.60 and a two-hundred day simple moving average of $1.91. The firm has a market capitalization of $3.59 million, a PE ratio of -0.07 and a beta of 1.10.

VolitionRX Company Profile

(Get Free Report)

VolitionRx Limited is a life sciences company developing blood-based diagnostic tests for cancer and other diseases. The company’s technology is based on nucleosomes, fragments of DNA and associated proteins released into the bloodstream during cell death, which may provide information useful for disease detection, monitoring and treatment decisions.

VolitionRx’s product development activities include its Nu.Q technology platform and Nu.Q Vet, a suite of veterinary cancer screening and monitoring tests designed for use in dogs and other companion animals.

Further Reading

• Five stocks we like better than VolitionRX
• Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
• Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
• AMD Chips Away at NVIDIA’s AI Throne
• Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.